1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese Language Podcast: Biokin/BMS Deal, Developments At Pfizer, BlissBio, WuXi Biologics

Latest China Biopharma Moves Discussed

 
• By Brian Yang and Dexter Jie Yan

Chengdu-based Biokin has just signed a $8.4bn licensing deal with BMS for an ADC asset, while Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in China. Meanwhile, BlissBio has released new clinical data for its HER2-targeting ADC and shares in WuXi Biologics have plummeted following its latest business updates.

Chinese biotech podcast
audio roundup of latest Chinese biopharma topics • Source: Citeline/Shutterstock

Chinese antibody-drug conjugate developers are making further inroads in global biotech dealmaking, with Chengdu-based Biokine Therapeutics Ltd.’s US subsidiary recently inking a megadeal with Bristol Myers Squibb Company worth up to $8.4bn in total.

On 5 December, Hong Kong-listed WuXi Biologics saw a single-day share price plunge of over 23%, following a business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.

More from Focus On Asia

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.